Budget impact analysis of treatment-free remission in nilotinib-treated Japanese chronic myeloid leukemia patients.

ABSTRACT: Treatment-free remission (TFR), in which patients discontinue pharmacotherapy and remain in molecular remission, is an emerging treatment goal for patients with chronic myeloid leukemia (CML). Attainment of TFR requires an increased frequency of molecular monitoring, to ensure that patients maintain a deep molecular response. The objective of this analysis was to assess the economic impact of stopping nilotinib among Japanese TFR-eligible patients. A Markov model evaluated the economic impact of TFR among the study population, TFR-eligible CML patients diagnosed since 2012. The model compared patients who had discontinued tyrosine kinase inhibitor (TKI) treatment (ie, attempted TFR) with patients that continued TKI treatment. A 3-y time horizon was modeled from a Japanese public payer pers

SUBMITTER: Yamazaki K 

PROVIDER: S-EPMC7385357 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature